Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data

The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting ≥4 months (ORR4; primary endpoint) and progression-free survival (PFS) with brentuximab vedotin vs physician’s choice (methotrexate or bexarotene) in CD30-expressing mycosis fungoides (MF) or...

Descripción completa

Detalles Bibliográficos
Autores principales: Horwitz, Steven M., Scarisbrick, Julia J., Dummer, Reinhard, Whittaker, Sean, Duvic, Madeleine, Kim, Youn H., Quaglino, Pietro, Zinzani, Pier Luigi, Bechter, Oliver, Eradat, Herbert, Pinter-Brown, Lauren, Akilov, Oleg E., Geskin, Larisa, Sanches, Jose A., Ortiz-Romero, Pablo L., Weichenthal, Michael, Fisher, David C., Walewski, Jan, Trotman, Judith, Taylor, Kerry, Dalle, Stephane, Stadler, Rudolf, Lisano, Julie, Bunn, Veronica, Little, Meredith, Prince, H. Miles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153035/
https://www.ncbi.nlm.nih.gov/pubmed/34507350
http://dx.doi.org/10.1182/bloodadvances.2021004710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153035/
https://www.ncbi.nlm.nih.gov/pubmed/34507350
http://dx.doi.org/10.1182/bloodadvances.2021004710

Ejemplares similares